drugset / Trial / NCT00662740

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00662740

Phase 3 Terminated 220 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea Index (BDI/TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations.

Timeline

Start
2008-04-15
Primary completion
2008-11-21
Completion
2008-11-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salmeterol Other / unclassified Inhaled
Comparator Tiotropium Other / unclassified Inhaled